Table 1.
Baseline characteristics, clinical information of the studied population and relevant ECMO dataa
| Demographic and ECMO data | Result (n = 14) |
|---|---|
| Demographic characteristics | |
| Male | 7 (50) |
| Age, years | 36 (34–52) |
| Weight (kg) at admission | 76 (68–89) |
| Body mass index (kg/m2) | 26 (23–28) |
| Number of patients on RRT | 3 (21) |
| CVVH | 1 (33) |
| CVVHD | 1 (33) |
| CVVHDF | 1 (33) |
| No. of patients by indication for ECMO | |
| Respiratory failure | 9 (64) |
| Cardiogenic shock | 2 (14) |
| Cardiac arrest | 2 (14) |
| Heart transplant | 1 (7) |
| Illness severity score | |
| APACHE II (on admission) | 17 (14–19) |
| SOFA (on sampling day) | 8 (6–11) |
| CrCL (mL/min)b | 71 (57–143) |
| Albumin (g/L) | 27 (22–30) |
| Bilirubin (μmol/L) | 16 (11–28) |
| Total protein (g/L) | 52 (50–56) |
| Urea (mmol/L) | 7 (5–11) |
| No. of patients by dosing regimen administereda | |
| 1 g q24h | 2 (14), of which 1 (7) on RRT |
| 1 g q12h | 8 (57), of which 2 (14) on RRT |
| 2 g q24h | 1 (7) |
| 2 g q12h | 3 (21) |
| ECMO circuit data | |
| ECMO modality | |
| Veno-venous | 9 (64) |
| Veno-arterial | 5 (36) |
| ECMO pump | |
| Jostra Rota flow | 11 (79) |
| CardioHelp | 2 (14) |
| Levitronix Centrimag | 1 (7) |
| ECMO oxygenator | |
| Maquet Quadrox | 10 (71) |
| Medos Hilite | 3 (21) |
| Medtronic affinity | 1 (7) |
| Flow rate (L/min) | 4.2 (3.2–5.2) |
| Days on ECMO before sampling | 3 (1–4) |
APACHE II acute physiology and chronic health evaluation II score, CrCL creatinine clearance, CVVH continuous venovenous haemofiltration, CVVHD continuous venovenous haemodialysis, CVVHDF continuous venovenous haemodiafiltration, ECMO extracorporeal membrane oxygenation, RRT renal replacement therapy, SOFA sequential organ failure assessment
aData are presented as median (interquartile range) or n (%) unless otherwise indicated
bData for 11 patients not on RRT